Brendan Smith
Stock Analyst at TD Cowen
(1.21)
# 3,451
Out of 4,734 analysts
6
Total ratings
40%
Success rate
-0.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $11.58 | -13.64% | 1 | Sep 20, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $55.94 | +16.20% | 2 | Aug 7, 2024 | |
| NVAX Novavax | Maintains: Hold | $5 → $10 | $8.81 | +13.51% | 1 | May 13, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $19.76 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $23.04 | - | 1 | Dec 5, 2022 |
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $11.58
Upside: -13.64%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $55.94
Upside: +16.20%
Novavax
May 13, 2024
Maintains: Hold
Price Target: $5 → $10
Current: $8.81
Upside: +13.51%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $19.76
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $23.04
Upside: -